MLKL and Alzheimer disease: Elevated levels of RIPK1 and RIPK3 can trigger necroptosis, a programmed cell death pathway, and increased tumor necrosis factor receptor-1 (TNFR1) signaling in AD further promotes necroptosis through the RIPK1/RIPK3/MLKL pathway 131.